Chris has joined Samsara as Head of Public Research in December 2020. He currently serves on the Board of Leap Therapeutics and is an observer on a number of private company Boards.
Previously, he was an SVP, Research for almost six years at Tekla Capital Management where Chris covered the biotechnology and pharmaceutical sectors, both public and private and across all size companies. Prior to Tekla, Chris was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, Chris spent five years in the Allergy/Immunology Group at the Schering-Plough Research Institute.
He has a BS in Cellular and Molecular Biology from Purchase College and both an MS in Biochemistry and an MBA in Finance from NYU.